الفهرس 
Virology and life cycle of HCVOnly 14 pages are availabe for public view
 |  | from | 190 |  |  |
| | | from | 190 | | |
Abstract
Introduction and aim:
Fatigue is probably the most common extra hepatic manifestation of HCV infection as about 60% report disabling chronic fatigue also depression has been reported in about one third of HCV-infected patients. The study aimed to evaluate fatigue and depression in hepatitis C virus (HCV) patients before and after treatment (4 weeks and 3 months) by Direct Acting Antiviral Drugs (DAAs).
Patients and methods:
The study included a total of 150 Patients with chronic HCV receiving direct acting antiviral drugs (DAAs). All patients were assessed for presence of fatigue by chalder fatigue scale and for presence of depression by beck’s depression inventory scale. The assessment was done before treatment and after the end of treatment by 4 weeks and by 3 months. Also full history taking, thorough clinical examination, laboratory investigations and pelvi-abdominal ultrasound were done before treatment and after the end of treatment by 4 weeks and by 3 months.
Results and conclusion:
Before treatment 120 (80%) of our patients had fatigue and 78 (52%) of our patients had depression, One month after the end of treatment fatigued patients decreased to be 49 (32.7%) and the number of depressed patients decreased to 33 (22%), and at sustained virological response (3 months after the end of treatment); the number further decreased to be only 21 (14%) of our patients still have fatigue and number of depressed patients further decreased to be 20 (13.4%) of our patients still have depression. fatigue scores increase with older age and presence of diabetes and anemia, depression prevalence and severity are higher in females and anemic patients. Higher Fib4 score and ALT level are associated with higher fatigue and depression scores.